Navigation Links
Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
Date:1/8/2010

l drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infection, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in the phase 1b INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates include PSI-7851, an unpartnered, next generation HCV nucleotide analog, that has completed initial Phase 1 clinical studies which provided supportive safety and efficacy data to initiate a Phase 2a trial in 1Q 2010 and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.

Pegasys® and Copegus® are registered trademarks of Roche.


    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of

1995: Statements in this press release regarding our business that are not historical facts are

"forward-looking stateme
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2009 Financial Results
2. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
3. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
5. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
6. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
7. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
8. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
9. Pharmasset Reports Fiscal Year End 2008 Financial Results
10. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
11. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Saint-Gobain has acquired ZenPure, ... filtration products, mainly for the life sciences sector. ... in a state-of-the-art plant in Hangzhou, China ... the globe and will bolster the range of fluid ... acquisition is fully in line with the Group,s strategy ...
(Date:5/6/2015)...  Membership in Medicare Supplement plans continued to ... Strategy report released by Mark Farrah Associates (MFA).  ... Med Supp plans, covered approximately 11.2 million seniors ... from 2013. Between 2013 and 2014, enrollment in ... Though UnitedHealth was the segment growth leader, many ...
(Date:5/6/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/7qn2gf/global_insulin ) ... Insulin Patch Market Opportunity Analysis" report to ... ultrasound and iontophoresis are being used for the ... type of technique, their prices may vary which ... In long-term, it would be considered as inexpensive ...
Breaking Medicine Technology:Saint-Gobain Acquires ZenPure, a Specialist in Filtration Products 2Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Global Insulin Patch Market Opportunity Analysis 2015 2
(Date:5/6/2015)... (PRWEB) May 07, 2015 Device Patent Law ... 2015 — 11:00 a.m. – 12:30 p.m. EDT, http://www.fdanews.com/DevicePatentLaw ... in expensive patent lawsuits and claims that waste their time. ... of these cases could be prevented if devicemakers better understand ... latest court rulings and revisions to patent laws from all ...
(Date:5/6/2015)... 2015 As the exclusive hospital of the ... the Pirate Ship at Raymond James Stadium for all the ... first to be drafted into the “Bucs Babies” program last ... spend time with children, particularly those born at the Florida ... be Buccaneers fans. I really enjoyed my time participating in ...
(Date:5/6/2015)... 06, 2015 On April 27, 2015, ... Plastic Surgery ,” compiled quotes about cosmetic surgery from ... pop singer Iggy Azalea, and Gwyneth Paltrow. For the ... having plastic surgery themselves; only a couple ... its expectations of youth and beauty. (see: goo.gl/wSomih) , ...
(Date:5/6/2015)... Chesapeake, Va. (PRWEB) May 06, 2015 ... hospital in the state of Virginia to acquire ... Vinci® surgical robot. The system upgrade includes enhanced ... many minimally invasive procedures across a wide spectrum ... surgical options, reduced pain and quicker recovery times. ...
(Date:5/6/2015)... King of Prussia, PA (PRWEB) May 06, 2015 ... Business Process Outsourcing solutions to the Medicare Advantage, Medicare ... three finalists in the Continuity and Resilience Team category ... by the Business Continuity Institute to recognize the outstanding ... or operating in the North America Region, including the ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 2Health News:FDAnews Announces — Device Patent Law Changes: Six Key Areas of Concern Webinar, May 27, 2015 3Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 2Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 3Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... CHICAGO, Jan. 26 The YMCA of Metropolitan Chicago ... residents to lead healthier lifestyles.According to the U.S. Department ... report they are not physically active. Poor diet and ... are overweight or obese are at increased risk for ...
... warm up chilly Chicago bus riders by heating ten bus shelters in the downtown area. ... following locations:, , 16 South ... @ Lake , 300 North Michigan Avenue @ Wacker ... 757 North Michigan Avenue @ Chicago , ...
... glucose scored worse on cognition tests, study found , , MONDAY, ... diabetes, higher average blood glucose (sugar) levels may be linked ... Researchers found that patients with higher levels of hemoglobin A1C ... 3 months) had significantly worse results while doing cognitive tasks ...
... an uncommon, but possible, reaction, study finds, , , ... take medications for attention-deficit hyperactivity disorder (ADHD) may ... hallucinations. , U.S. government experts reviewed clinical ... the commonly prescribed ADHD stimulant medications, such as ...
... Ill., Jan. 26 /PRNewswire/ -- Alma ... and radiofrequency-based aesthetic devices, announced today the FDA ... The UniForm is the fifth module available ... UniForm has received FDA clearance for "the temporary ...
... Prevent serious injuries from ,extreme, winter sports by following ... For many thrill-seekers, extreme ("x-treme") sports can be a ... long winter months. Recently televised events such as the ... sports, including downhill ski racing and jumping, snowboarding, snowmobiling, ...
Cached Medicine News:Health News:YMCA and Dominick's Offer Health and Wellness Options 2Health News:It's Cold Outside! Warm Up in Select Downtown Chicago Heated Bus Shelters Courtesy of TYLENOL(r) Warming Liquids 2Health News:Higher Blood Sugar Could Impair Thinking 2Health News:Hallucinations Are Rare Side Effects of ADHD Medications 2Health News:'X-Tremely' Dangerous Sports 2Health News:'X-Tremely' Dangerous Sports 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: